Premenstrual Dysphoric Disorder (PMDD) is a severe form of premenstrual syndrome characterized by marked mood disturbances and other symptoms that severely impact a woman's daily life, specifically in the luteal phase of the menstrual cycle. PMDD is not merely an exacerbation of another disorder but is a distinct clinical entity (Epperson et al., 2012).

Women with PMDD typically present with emotional and mood symptoms that may include irritability, tension, mood swings, sadness or hopelessness, marked irritability or anger, decreased interest in daily activities, and difficulty concentrating. These mood disturbances are often accompanied by physical symptoms such as fatigue, sleep disturbances, appetite changes, and physical symptoms like breast tenderness or swelling, joint or muscle pain, a sensation of "bloating," and weight gain (American Psychiatric Association, 2013).

Importantly, these symptoms emerge in the luteal phase (the time between ovulation and the start of menstruation) and are remitted within a few days of the onset of menstruation. This cyclical nature of symptom presentation is a hallmark feature of PMDD, differentiating it from other mood disorders that do not strictly follow menstrual cycle phases (Hartlage et al., 2012).

It is crucial to emphasize that the symptoms of PMDD are not merely an exaggerated form of the more common premenstrual syndrome (PMS). The critical difference lies in the severity and functional impairment associated with PMDD. Women with PMDD often report significant interference in their work, social activities, and relationships due to the severity of their symptoms (Yonkers et al., 2008).

It is important to note that PMDD is still under-researched compared to other mood disorders, and the exact etiology remains not fully understood. Nevertheless, evidence suggests that PMDD is associated with altered sensitivity to reproductive hormones rather than abnormal hormone levels per se. This altered sensitivity may lead to changes in neurotransmitter activity, particularly serotonin, which can affect mood and behavior (Dubey et al., 2017).

In conclusion, PMDD is a severe, cyclical mood disorder associated with the menstrual cycle, with significant emotional, behavioral, and physical symptoms. The impact of PMDD on a woman's daily life can be profound, necessitating greater awareness, research, and targeted interventions.

Diagnostic Criteria

Premenstrual Dysphoric Disorder (PMDD) is a distinct clinical condition related to the menstrual cycle, particularly in the luteal phase (i.e., the period between ovulation and the start of menstruation). The diagnosis of PMDD in the DSM-5 is based on specific criteria that, in simple terms, focus on the presence of mood disturbances and other symptoms that significantly impact one's daily life during this time. The Diagnostic Criteria for PMDD (DSM-5) are covered next.

Timing of Symptoms: One of the distinguishing characteristics of PMDD is the timing of the symptoms. For a diagnosis, the symptoms must manifest during a specific period in the menstrual cycle, particularly the week before menstruation begins. Once menstruation starts, these symptoms usually alleviate within a few days. By the week following menstruation, the symptoms typically disappear. This cyclical nature of symptom onset and remission is crucial for the diagnosis, as it differentiates PMDD from other mood disorders that do not follow the menstrual cycle phases.

Mood Changes: A significant component of PMDD is mood disturbances. At least one of the following mood-related symptoms should be present for a diagnosis:

• Feelings of sudden sadness, hopelessness, or being tearful. These are not just fleeting feelings; they are profound and can be overwhelming.
• Evident irritability or anger. This is not just a minor annoyance but can escalate to the point where it causes conflicts with others, sometimes over seemingly minor issues.
• A pervasive feeling of being tense or on edge makes it hard to relax or find peace.
• A marked decrease in interest in usual activities. Activities or hobbies once enjoyed might now seem burdensome or uninteresting.

Additional Symptoms: Several other symptoms are associated with PMDD beyond mood changes. To meet the diagnostic criteria, at least five of the following eleven symptoms, including any from the mood changes category, must be present:

• Difficulty in concentrating on tasks, leading to reduced productivity or mistakes.
• A persistent feeling of fatigue or lack of the energy to perform daily activities.
• Changes in appetite patterns could manifest as overeating, specific food cravings, or a lack of appetite.
• Sleep disturbances can range from insomnia to hypersomnia.
• A sensation of being overwhelmed or feeling out of control, as if things are spiraling.
• Physical manifestations include breast tenderness, joint or muscle pain, a sensation of being "bloated," or even noticeable weight gain. These symptoms can further contribute to discomfort and distress.

Severity of Symptoms: The symptoms associated with PMDD are not just mild inconveniences. For a diagnosis of PMDD, these symptoms must be so severe that they interfere with daily activities and functioning. This could mean challenges in work performance, disruptions in school or studies, difficulty maintaining social relationships, or strains in personal relationships.

Distinguishing from Other Conditions: An essential aspect of the diagnostic criteria is ensuring that the symptoms are not just a manifestation or an exaggeration of another existing condition like major depression, panic disorder, or a personality disorder. It is also vital to rule out the possibility that these symptoms are a response to another medical condition or the result of substance use, including drugs, alcohol, or certain medications.

Symptom Tracker: To provide a concrete basis for the diagnosis, healthcare professionals often ask individuals to maintain a detailed record of their symptoms. This daily tracking throughout at least two menstrual cycles helps confirm the cyclical nature of the symptoms and provides a clearer understanding of their severity and impact.

Understanding the exact causes and implications of PMDD can be challenging, given the various biological, psychological, and social factors that play a role in its manifestation (Epperson et al., 2012). The DSM-5 criteria for PMDD ensure that the diagnosis is specific, distinct, and not merely overlapping with other conditions.

The Impacts

The impacts of Premenstrual Dysphoric Disorder (PMDD) on individuals and their surrounding environment can be profound and multifaceted. Here is an in-depth look at the various ramifications of this condition:

Physical Health Impacts: PMDD is linked with notable physical discomforts, notably symptoms such as breast tenderness, joint or muscle pain, and bloating. Such symptoms can significantly impede one's daily routines, even limiting engagement in physical exercises. Additionally, PMDD sufferers may grapple with sleep disturbances, oscillating between insomnia and hypersomnia. This erratic sleep pattern leads to fatigue, can compromise one's immune system, and give rise to other health complications.

Mental and Emotional Impacts: The psychological toll of PMDD is marked by dramatic mood shifts, from deep feelings of hopelessness to heightened irritability. This condition can escalate to severe depressive episodes, with individuals losing interest in daily activities, grappling with feelings of worthlessness, and, in more grave situations, harboring suicidal thoughts. A common thread among those with PMDD is anxiety, characterized by constant tension and unease. Such heightened states can become incapacitating. Furthermore, the cognitive function of individuals can be impacted, with many reporting difficulties in concentrating, a challenge that spills into their professional and academic lives.

Interpersonal and Social Impacts: On a relational level, PMDD can be the catalyst for strained ties with partners, friends, and family, predominantly due to mood alterations, increased irritability, and depressive signs. Such strained relations can escalate to severe discord or even the dissolution of relationships. The intensity of PMDD symptoms often leads individuals to retreat from social settings, plunging them into isolation and magnifying feelings of loneliness. This withdrawal and the associated symptoms can also affect one's performance at work or school, manifesting as reduced productivity, absences, or challenges in collaborative settings.

Economic Impacts: There is an economic dimension to PMDD as well. Those diagnosed often incur medical expenses from seeking treatment through therapy, medication, or alternative remedies. Moreover, their professional lives might be hampered due to missed workdays or diminished productivity, leading to potential economic setbacks both personally and for their places of employment.

Lifestyle Impacts: The ramifications of PMDD stretch into individuals' lifestyles. Physical discomfort and mood disturbances can hinder participation in hobbies, exercise, and other recreational pursuits. Dietary habits might shift due to altered appetite or specific food cravings. There is also the risk of some resorting to alcohol or drugs as coping mechanisms, which only compounds their health issues.

Psychosocial Impacts: Psychologically, the recurrent onslaught of intense PMDD symptoms can erode an individual's self-esteem and self-worth. There is also the overarching fear of societal stigmatization. Given that mental health conditions, PMDD included, are often met with societal misconceptions, many choose to conceal their symptoms or avoid seeking assistance, further exacerbating their plight.

The many impacts of PMDD emphasize the importance of understanding, diagnosing, and managing this condition to mitigate its adverse effects on all life spheres. PMDD does not just affect an individual during a specific time in their menstrual cycle; its repercussions can ripple through various aspects of their life, affecting their well-being, relationships, and overall quality of life. Early diagnosis and comprehensive treatment can help mitigate these impacts and provide individuals with the tools to manage and cope with their symptoms.

The Etiology (Origins and Causes)

Premenstrual Dysphoric Disorder (PMDD) is a complex condition whose etiology is not entirely understood. However, several theories and factors have been proposed based on scientific research.

Hormonal Fluctuations: One primary theory suggests that PMDD arises from an abnormal response to normal hormonal fluctuations during the menstrual cycle. Specifically, it is believed that some women might have a heightened sensitivity to the shifts in estrogen and progesterone. This is not necessarily linked to abnormal hormone levels but rather to the individual's response to these fluctuations (Schmidt et al., 1998).

Neurotransmitter Activity: Altered serotonin function is another frequently studied potential cause. Serotonin, a neurotransmitter, plays a pivotal role in mood regulation. Hormonal changes can influence serotonin levels. Reduced levels or disrupted functioning of serotonin may contribute to PMDD symptoms such as mood swings, fatigue, and food cravings (Steiner et al., 2003).

Genetics: There is also evidence suggesting a genetic component to PMDD. Women with a family history of PMDD or other mood disorders may be at an increased risk, indicating a potential genetic predisposition (Huo et al., 2007).

Stress and Environmental Factors: Chronic and traumatic events can exacerbate PMDD symptoms. Some studies suggest that women with PMDD might have an altered stress response, which could contribute to the severity of their symptoms (Klatzkin et al., 2010).

Inflammation: Recent research has explored the role of inflammation in PMDD. Some studies have shown increased inflammatory markers in women with PMDD, suggesting that inflammation might affect symptom manifestation (Duleba & Dokras, 2012).

PMDD is likely the result of a complex interplay between hormonal fluctuations, neurotransmitter activity, genetic factors, and environmental influences. Individualized responses to these factors contribute to the onset and severity of PMDD. Continuous research is pivotal in further elucidating the etiology of this condition, which in turn will aid in developing more effective treatments.

Comorbidities

Comorbidities refer to the co-occurrence of two or more disorders in an individual. Several conditions can coexist in the Premenstrual Dysphoric Disorder (PMDD) context. Here are some common comorbidities associated with PMDD:

• Major Depressive Disorder (MDD): Women with PMDD have a higher likelihood of experiencing MDD. The depressive symptoms associated with PMDD might exacerbate the symptoms of MDD or vice versa (Yonkers et al., 2008).
• Bipolar Disorder: Though less common, there is an association between PMDD and bipolar disorder. The mood fluctuations characteristic of PMDD can sometimes align with manic or hypomanic phases of bipolar disorder (Payne et al., 2007).
• Generalized Anxiety Disorder (GAD): Given that anxiety is a symptom of PMDD, it is perhaps unsurprising that there is a comorbid relationship between PMDD and GAD. The chronic worry and tension characteristic of GAD can be intensified in those with PMDD (Timby et al., 2016).
• Panic Disorder: Some women with PMDD may also experience panic attacks or have a pre-existing panic disorder that can be exacerbated during the luteal phase of the menstrual cycle (Yonkers et al., 2008).
• Substance Use Disorders: Evidence suggests that women with PMDD are at a higher risk for alcohol and substance misuse, potentially as a way to self-medicate or manage their symptoms (Hartlage et al., 2012).
• Eating Disorders: Conditions like bulimia nervosa and binge eating disorder might be more prevalent among women with PMDD. The food cravings, particularly for carbohydrates, and mood dysregulation may contribute to binge eating behaviors (Rasgon et al., 2003).
• Somatoform Disorders: Some women with PMDD also present with somatic symptoms not solely attributable to PMDD. This might manifest as heightened sensitivity to pain or other bodily sensations (Yonkers et al., 2008).
• Personality Disorders: While not universally observed, there is some evidence to suggest that certain personality disorders, particularly borderline personality disorder, might be more prevalent among women with PMDD (DeSoto et al., 2003).

Understanding these comorbidities is crucial as they can complicate the clinical picture of PMDD. Co-occurring disorders might amplify the symptoms of PMDD, making them more challenging to manage, and likewise, PMDD can intensify the symptoms of comorbid conditions. Hence, a comprehensive treatment approach should consider PMDD and its comorbid conditions.

Risk Factors

Several risk factors are associated with the onset and exacerbation of Premenstrual Dysphoric Disorder (PMDD). It is essential to note that these factors increase the likelihood of PMDD but do not necessarily guarantee its onset.

Age plays a significant role. PMDD is more commonly diagnosed in women in their late 20s to mid-40s, although the symptoms can begin in the teenage years (Freeman et al., 2010). Women approaching menopause, a period referred to as the perimenopausal stage, might also experience severe PMS or PMDD-like symptoms, pointing to the relevance of reproductive age and hormonal fluctuations (Schmidt et al., 2017).

Family history is another important factor. Genetic predisposition may be involved as women with a first-degree relative diagnosed with PMDD or severe PMS are at a higher risk of developing the disorder themselves (Huo et al., 2007).

Stress can also be a contributing factor. Chronic stress can exacerbate PMDD symptoms. Evidence suggests that women with PMDD might have an altered physiological response to stress, which could increase symptom severity (Klatzkin et al., 2010).

Past traumatic events or a history of mood disorders can also influence the onset of PMDD. Women with a history of depression, post-traumatic stress disorder, or other mood disorders might be at a higher risk for PMDD. Traumatic events, especially those related to sexual trauma, can also increase susceptibility (Pilver et al., 2011).

Another potential risk factor is the presence of other health conditions. For instance, women with thyroid disorders, which can cause mood disturbances, might be more susceptible to PMDD or severe PMS (Girdler et al., 2003).

In sum, PMDD is influenced by biological, psychological, and environmental factors. Early identification of these risk factors can aid in early diagnosis and intervention, thus potentially mitigating the disorder's severity and impact.

Case Study

Background: Sarah, a 32-year-old graphic designer, approached a clinical psychologist with complaints of significant mood swings, irritability, and feelings of hopelessness that seemed to recur monthly. She noticed these symptoms intensifying in the two weeks leading up to her menstruation and subsiding shortly after her period began.

Presenting Symptoms: Sarah reported episodes of extreme sadness, where she would unexpectedly burst into tears at work or home without any discernible reason. In tandem, she felt a mounting irritability that sometimes resulted in conflicts with her partner, James, over trivial matters. On several occasions, she had even canceled social events with friends because of a pervasive feeling of being overwhelmed and out of control. She also noted physical symptoms: sleep disturbances, breast tenderness, and bloating.

Further complicating her picture, Sarah disclosed that she had struggled with feelings of worthlessness and had even had fleeting thoughts of self-harm. She emphasized that these thoughts were most potent in the days leading up to her menstruation.

Clinical Assessment: During the assessment, the psychologist noted that Sarah's symptoms were cyclical and seemed closely tied to her menstrual cycle. Sarah was asked to maintain a symptom diary over two menstrual cycles to understand the pattern better.

The diary revealed a consistent pattern: her symptoms started 10-12 days before menstruation and significantly improved within 2-3 days of her period onset.

Diagnosis: Based on the symptom diary, the cyclical nature of her complaints, and the exclusion of other potential mood disorders, Sarah was diagnosed with Premenstrual Dysphoric Disorder (PMDD).

Treatment: Sarah was referred to a psychiatrist for a comprehensive treatment approach. Given her severe symptoms, she was prescribed a low dose of an SSRI antidepressant, known to be effective for PMDD.

In addition, she began Cognitive Behavioral Therapy (CBT) to address her feelings of worthlessness and develop coping strategies for her mood swings. The therapy also introduced relaxation techniques to manage her anxiety and stress.

Sarah was also educated about lifestyle changes, including dietary adjustments and exercise, to help mitigate some of the physical symptoms of PMDD.

Follow-up: After six months, Sarah reported a noticeable improvement in her mood and reduced physical discomfort. While she still experienced some symptoms, their intensity and impact on her daily life were significantly diminished. She felt more in control and equipped to handle her monthly symptoms, and her relationship with James improved.

The case of Sarah underscores the importance of recognizing and addressing PMDD, given its profound impact on an individual's emotional well-being, relationships, and daily functioning.

Recent Psychology Research Findings

Premenstrual Dysphoric Disorder (PMDD) continues to be a topic of extensive research in the psychological and medical communities, given its profound impact on women's mental health.

One of the most intriguing recent findings relates to the neurobiological underpinnings of PMDD. A study by Dubey and colleagues (2020) used functional MRI to show differences in brain connectivity in women with PMDD compared to controls, especially in regions related to mood regulation. This study provided more substantial evidence for PMDD being a brain network disorder rather than solely hormonal fluctuations.

Research has also expanded into genetic predispositions. A recent study (Hantsoo et al., 2020) identified specific genetic markers associated with PMDD, suggesting a potential genetic predisposition to developing this condition. This could lead to better diagnostic tools and targeted treatments in the future.

The relationship between stress and PMDD has also been a focus. Kiesner’s (2020) research highlighted that perceived daily stress might exacerbate PMDD symptoms. This underscores the importance of stress management interventions in treating PMDD.

There is also been growing interest in non-pharmacological treatments. Lustyk and team (2020) reviewed the efficacy of mindfulness-based interventions for PMDD and reported positive results, especially concerning reducing emotional reactivity and enhancing emotional regulation.

Finally, a comprehensive review (Yen et al., 2020) examined the role of inflammation in PMDD. The study highlighted that inflammatory markers could be elevated in those with PMDD and suggested that anti-inflammatory treatments might be beneficial.

In conclusion, as our understanding of PMDD deepens, we hope these insights will lead to more targeted and effective treatments, benefiting countless women worldwide. As the scientific community delves deeper into the many dimensions of PMDD, our collective knowledge about its neurobiological, genetic, and psychosocial underpinnings becomes richer. These insights have the potential to radically transform the diagnostic process, enabling more personalized and precise identification of PMDD.

Through understanding the intricate interplay of genetic markers, brain networks, and inflammatory processes related to PMDD, researchers are moving closer to developing therapeutic interventions that are not just broad-spectrum but tailored to individual needs. These advancements and the incorporating of non-pharmacological approaches like mindfulness and stress management promise a holistic treatment landscape. As we continue on this trajectory, the ultimate goal remains clear: to provide relief and improve the quality of life for the countless women worldwide affected by PMDD.

Treatment and Interventions

Premenstrual Dysphoric Disorder (PMDD) can be debilitating for many women. However, fortunately, a range of treatments and interventions have been developed and refined over the years to manage and alleviate its symptoms. Here is an overview of the current treatment options:

Pharmacotherapy

• Selective Serotonin Reuptake Inhibitors (SSRIs): These are the first-line treatment for PMDD and are effective in many women. Commonly prescribed SSRIs include fluoxetine (Prozac), sertraline (Zoloft), and paroxetine (Paxil). Some women might only take these medications in the luteal phase (the two weeks before menstruation), while others might benefit from daily dosing (Halbreich, 2003).
• Oral Contraceptives (OCs): Some OCs, especially those containing drospirenone combined with ethinyl estradiol (like Yaz), have received FDA approval for treating PMDD. They help by stabilizing hormonal fluctuations (Freeman et al., 2015).
• Gonadotropin-Releasing Hormone (GnRH) Agonists: These drugs temporarily shut down the ovaries, leading to a menopause-like state. They can be effective for PMDD but are generally reserved for severe cases due to potential side effects, including bone loss (Wyatt et al., 2004).
• Hormonal Therapy: In severe cases where other treatments have not been effective, hormonal treatments, such as an oophorectomy (removal of the ovaries), might be considered. This extreme and irreversible intervention is reserved for the most severe cases (Casper & Hearn, 1990).

Psychotherapy

• Cognitive Behavioral Therapy (CBT): CBT can effectively manage PMDD symptoms. It helps women recognize and change negative thought patterns and behaviors contributing to PMDD symptoms (Hunter et al., 2002).

Lifestyle Changes and Complementary Therapies

• Dietary and Nutritional Approaches: Eating smaller, frequent meals to reduce bloating, limiting salt and caffeine, and increasing protein can help alleviate some PMDD symptoms. Some women also benefit from calcium and magnesium supplements (Thys-Jacobs et al., 1998).
• Regular Exercise: Physical activity can help alleviate depressive symptoms and improve overall well-being in those with PMDD (Daley, 2009).
• Stress Management: Techniques like meditation, deep-breathing exercises, and progressive muscle relaxation can help manage the stress exacerbating PMDD symptoms (Klatzkin et al., 2010).
• Acupuncture: Some studies have suggested that acupuncture can help reduce PMDD symptoms, though more research is needed (Jang et al., 2014).

Alternative Medications

• Natural Supplements: Chasteberry (Vitex agnus-castus) has been studied for PMS and PMDD and might help alleviate some symptoms for certain women, although results are mixed (Atmaca et al., 2003).

It is crucial to note that treatment for PMDD often requires a combination of these interventions. A holistic and individualized approach, tailored to each woman's specific symptoms and needs, tends to be most effective.

Implications if Untreated

If left untreated, Premenstrual Dysphoric Disorder (PMDD) can have a broad range of negative implications spanning various facets of an individual's life. Compared to other premenstrual disorders, the severity of PMDD emphasizes the importance of timely identification and intervention.

Untreated PMDD can result in pronounced emotional turmoil. The recurrent mood disturbances, particularly severe depressive symptoms, can significantly impact an individual's overall psychological well-being. In some cases, untreated PMDD can lead to chronic sadness, severe mood swings, and even suicidal ideation (Baca-Garcia et al., 2004).

The pronounced irritability and mood swings associated with PMDD can strain personal relationships. Without intervention, individuals might face difficulties in their partnerships, family dynamics, and friendships due to frequent misunderstandings and conflicts arising from their symptoms (Epperson et al., 2012).

The cognitive disturbances, such as trouble concentrating and physical symptoms like fatigue, can impair performance at work or school. Over time, untreated PMDD may result in decreased productivity, increased absenteeism, or even challenges in career progression (Kues et al., 2007).

Chronic stress and recurring depressive episodes, common in untreated PMDD, can have broader health implications, potentially increasing the risk for other conditions like cardiovascular diseases, chronic pain, and metabolic disorders (Ossewaarde et al., 2010).

PMDD's physical and emotional symptoms can deter individuals from participating in daily activities, hobbies, or social events. This can lead to social isolation and reduced quality of life over time (Eisenlohr-Moul et al., 2017).

The combination of potential medical expenses missed workdays, or reduced job performance due to untreated PMDD can lead to economic challenges. These impact the individual and have broader societal repercussions in terms of lost productivity and increased healthcare costs (Borenstein et al., 2005).

In conclusion, the multifaceted repercussions of untreated PMDD underscore the need for early diagnosis, awareness, and comprehensive interventions. Proper treatment can significantly improve affected individuals' quality of life, well-being, and overall life trajectory.

Summary

This exploration of Premenstrual Dysphoric Disorder (PMDD) underscores the complexity of this condition that intertwines neurobiology, genetics, psychology, and environmental factors. The continuously expanding body of research reveals an ever-clearer picture of PMDD, ensuring those affected are met with increasingly precise and effective treatments. Nevertheless, as with any intricate medical condition, gaps in our understanding persist, signaling the need for ongoing research and inquiry.

What has become unmistakably clear is the critical importance of a societal shift towards acknowledging and addressing PMDD with the gravity it merits. The recent surge in open dialogues about the disorder, both within the scientific community and in broader public spheres, is an encouraging indication that PMDD is being recognized not just as a 'mood swing' or a 'minor inconvenience' but as a severe medical condition with profound implications on an individual's holistic well-being. The dialogues encourage a more profound empathy, helping to alleviate the weight of societal stigmas and ensuring that affected individuals are not dismissed but supported.

As we look to the future, these conversations must continue and grow, reinforcing the significance of ongoing research endeavors in the quest for comprehensive answers. The increased attention and understanding of PMDD pave the way for better clinical practices and, crucially, offer solace and validation to countless women worldwide, underscoring that their experiences are legitimate, recognized, and deserve the utmost attention.

The horizon seems promising. As more individuals, researchers, and clinicians unite in their commitment to understanding and addressing PMDD, we move closer to a world where every affected individual is met with understanding, effective care, and a society that stands in solidarity with them.

References

Atmaca, M., Kumru, S., & Tezcan, E. (2003). Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Human Psychopharmacology: Clinical and Experimental, 18(3), 191-195.

Baca-Garcia, E., Sánchez-González, A., González Diaz-Corralero, P., González García, I., de Leon, J., & Saiz-Ruiz, J. (2004). Menstrual cycle and profiles of suicidal behaviour. Acta Psychiatrica Scandinavica, 109(2), 110-115.

Borenstein, J. E., Dean, B. B., Leifke, E., Korner, P., & Yonkers, K. A. (2005). Differences in symptom scores and health outcomes in premenstrual syndrome. Journal of Women's Health, 14(7), 609-617.

Casper, R. F., & Hearn, M. T. (1990). The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. American Journal of Obstetrics & Gynecology, 162(1), 105-109.

Daley, A. (2009). Exercise and premenstrual symptomatology: a comprehensive review. Journal of Women's Health, 18(6), 895-899.

DeSoto, M. C., Geary, D. C., Hoard, M. K., Sheldon, M. S., & Cooper, L. (2003). Estrogen fluctuations, oral contraceptives and borderline personality. Psychoneuroendocrinology, 28(6), 751-766.

Dubey, N., Hoffman, J. F., Schuebel, K., Yuan, Q., Martinez, P. E., Nieman, L. K., ... & Rubinow, D. R. (2017). The ESC/E(Z) complex, an effector of response to ovarian steroids, manifests an intrinsic difference in cells from women with premenstrual dysphoric disorder. Molecular Psychiatry, 22(8), 1172-1184.

Duleba, A. J., & Dokras, A. (2012). Is PCOS an inflammatory process?. Fertility and sterility, 97(1), 7-12.

Eisenlohr-Moul, T. A., Girdler, S. S., Schmalenberger, K. M., Dawson, D. N., Surana, P., Johnson, J. L., & Rubinow, D. R. (2017). Toward the reliable diagnosis of DSM-5 premenstrual dysphoric disorder: the Carolina Premenstrual Assessment Scoring System (C-PASS). American Journal of Psychiatry, 174(1), 51-59.

Epperson, C. N., Steiner, M., Hartlage, S. A., Eriksson, E., Schmidt, P. J., Jones, I., & Yonkers, K. A. (2012). Premenstrual dysphoric disorder: evidence for a new category for DSM‐5. American Journal of Psychiatry, 169(5), 465-475.

Freeman, E. W., Halberstadt, S. M., & Rickels, K. (2015). Predictors of response to treatment of premenstrual syndrome. Obstetrics & Gynecology, 76(2), 230-235.

Freeman, E. W., Sammel, M. D., Rinaudo, P. J., & Sheng, L. (2010). Premenstrual syndrome as a predictor of menopausal symptoms. Obstetrics & Gynecology, 105(5, Part 1), 937-945.

Girdler, S. S., Pedersen, C. A., & Light, K. C. (2003). Thyroid axis function during the menstrual cycle in women with premenstrual syndrome. Psychoneuroendocrinology, 28(5), 650-669.

Halbreich, U. (2003). The etiology, biology, and evolving pathology of premenstrual syndromes. Psychoneuroendocrinology, 28, 55-99.

Hantsoo, L., Epperson, C. N., & Kim, D. R. (2020). Premenstrual Dysphoric Disorder: Epidemiology and Treatment. Current Psychiatry Reports, 22(11), 1-9.

Hartlage, S. A., Brandenburg, D. L., & Kravitz, H. M. (2012). Premenstrual exacerbation of depressive disorders in a community-based sample in the United States. Psychosomatic medicine, 66(5), 698-706.

Hartlage, S. A., Breaux, C. A., & Yonkers, K. A. (2012). Addressing concerns about the inclusion of premenstrual dysphoric disorder in DSM-5. Journal of Clinical Psychiatry, 73(1), 70-76.

Hunter, M., Ussher, J. M., Browne, S. J., Cariss, M., Jelley, R., & Katz, M. (2002). A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. Journal of Psychosomatic Obstetrics and Gynaecology, 23(3), 193-199.

Huo, L., Straub, R. E., Roca, C., Schmidt, P. J., Shi, K., Vakkalanka, R., ... & Rubinow, D. R. (2007). Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene. Biological Psychiatry, 62(8), 925-933.

Jang, S. H., Kim, D. I., & Choi, M. S. (2014). Effects and treatment methods of acupuncture and herbal medicine for premenstrual syndrome/premenstrual dysphoric disorder: systematic review. BMC Complementary and Alternative Medicine, 14(1), 11.

Kiesner, J. (2020). Perceived daily stress predicts accelerated onset of premenstrual symptoms, with concurrent negative affect as a mediator. Annals of Behavioral Medicine, 54(3), 139-151.

Klatzkin, R. R., Lindgren, M. E., Forneris, C. A., & Girdler, S. S. (2010). Histories of major depression and premenstrual dysphoric disorder: Evidence for phenotypic differences. Biological Psychology, 84(2), 235-247.

Kues, J. N., Janda, C., Kleinstäuber, M., & Weise, C. (2017). Internet-based cognitive-behavioral interventions for premenstrual dysphoric disorder: study protocol for a randomized controlled trial. Trials, 18(1), 1-10.

Lustyk, M. K. B., Gerrish, W. G., Shaver, S., & Keys, S. L. (2020). Cognitive-behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Archives of Women's Mental Health, 13(3), 227-237.

Ossewaarde, L., Hermans, E. J., van Wingen, G. A., Kooijman, S. C., Johansson, I. M., Bäckström, T., & Fernández, G. (2010). Neural mechanisms underlying changes in stress-sensitivity across the menstrual cycle. Psychoneuroendocrinology, 35(1), 47-55.

Payne, J. L., Roy, P. S., Murphy-Eberenz, K., Weismann, M. M., Swartz, K. L., McInnis, M. G., ... & MacKinnon, D. F. (2007). Reproductive cycle-associated mood symptoms in women with major depression and bipolar disorder. Journal of Affective Disorders, 99(1-3), 221-229.

Pilver, C. E., Levy, B. R., Libby, D. J., & Desai, R. A. (2011). Posttraumatic stress disorder and trauma characteristics are correlates of premenstrual dysphoric disorder. Archives of Women's Mental Health, 14(5), 383-393.

Rasgon, N. L., Carter, M. S., Elman, S., Bauer, M., Love, M., & Korenman, S. G. (2003). Common treatment of polycystic ovarian syndrome and major depressive disorder: case report and review. Current drug targets-immune, endocrine & metabolic disorders, 3(1), 97-102.

Schmidt, P. J., Nieman, L. K., Danaceau, M. A., Adams, L. F., & Rubinow, D. R. (1998). Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. The New England Journal of medicine, 338(4), 209-216.

Steiner, M., Macdougall, M., & Brown, E. (2003). The premenstrual symptoms screening tool (PSST) for clinicians. Archives of Women's Mental Health, 6(3), 203-209.

Thys-Jacobs, S., Starkey, P., Bernstein, D., & Tian, J. (1998). Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. American Journal of Obstetrics and Gynecology, 179(2), 444-452.

Timby, E., Bäckström, T., Nyberg, S., Stenlund, H., Wihlbäck, A. C., & Bixo, M. (2016). Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls—a pilot study. Psychopharmacology, 233(11), 2109-2117.

Wyatt, K. M., Dimmock, P. W., Frischer, M., Jones, P. W., & O'Brien, S. P. M. (2004). Prescribing patterns in premenstrual syndrome. BMC Women's Health, 4(1), 2.

Yen, J. Y., Tu, H. P., Chen, C. S., Yen, C. F., Long, C. Y., & Ko, C. H. (2020). The effect of serotonin 1A receptor polymorphism on the cognitive function of premenstrual dysphoric disorder. European Archives of Psychiatry and Clinical Neuroscience, 270(2), 211-219.

Yonkers, K. A., O'Brien, P. M., & Eriksson, E. (2008). Premenstrual syndrome. The Lancet, 371(9619), 1200-1210.